Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

2022-11-22
GENEVA, November 22, 2022--Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

Top 5 3rd Quarter Trades of MO - GuruFocus.com

2022-11-15
GuruFocus Article or News written by insider and the topic is about:

Needham Remains a Hold on Aerie Pharma (AERI)

2022-11-04
Needham analyst Serge Belanger maintained a Hold rating on Aerie Pharma (AERI – Research Report) today. The company’s shares opened today at $15.21. Bel...

Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates

2022-11-03
Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

2022-11-03
DURHAM, N.C., November 03, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022.

Aerie: Q3 Earnings Snapshot

2022-11-03
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Aerie Pharmaceuticals reports Q3 EPS (27c), consensus (44c)

2022-11-03
Reports Q3 revenue $36.1M... AERI

C WorldWide Group Holding A/S - GuruFocus.com

2022-11-03
GuruFocus Article or News written by insider and the topic is about:

The Zacks Analyst Blog Highlights SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals

2022-10-24
SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals are part of The Zacks top Analyst Blog.

Talaris (TALS) Down on Patient Death From Renal Transplant Study

2022-10-21
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.